BACKGROUND: The development of addiction is marked by a pathological associative learning process that imbues incentive salience to stimuli associated with drug use. Recent efforts to treat addiction have targeted this learning process using cue exposure therapy augmented with d-cycloserine (DCS), a glutamatergic agent hypothesized to enhance extinction learning. To better understand the impact of DCS-facilitated extinction on neural reactivity to drug cues, the present study reports fMRI findings from a randomized, double-blind, placebo-controlled trial of DCS-facilitated cue exposure for cocaine dependence. METHODS: Twenty-five participants completed two MRI sessions (before and after intervention), with a cocaine-cue reactivity fMRI task. The intervention consisted of 50mg of DCS or placebo, combined with two sessions of cocaine cue exposure and skills training. RESULTS: Participants demonstrated cocaine cue activation in a variety of brain regions at baseline. From the pre- to post-study scan, participants experienced decreased activation to cues in a number of regions (e.g., accumbens, caudate, frontal poles). Unexpectedly, placebo participants experienced decreases in activation to cues in the left angular and middle temporal gyri and the lateral occipital cortex, while DCS participants did not. CONCLUSIONS: Three trials of DCS-facilitated cue exposure therapy for cocaine dependence have found that DCS either increases or does not significantly impact response to cocaine cues. The present study adds to this literature by demonstrating that DCS may prevent extinction to cocaine cues in temporal and occipital brain regions. Although consistent with past research, results from the present study should be considered preliminary until replicated in larger samples.
RCT Entities:
BACKGROUND: The development of addiction is marked by a pathological associative learning process that imbues incentive salience to stimuli associated with drug use. Recent efforts to treat addiction have targeted this learning process using cue exposure therapy augmented with d-cycloserine (DCS), a glutamatergic agent hypothesized to enhance extinction learning. To better understand the impact of DCS-facilitated extinction on neural reactivity to drug cues, the present study reports fMRI findings from a randomized, double-blind, placebo-controlled trial of DCS-facilitated cue exposure for cocaine dependence. METHODS: Twenty-five participants completed two MRI sessions (before and after intervention), with a cocaine-cue reactivity fMRI task. The intervention consisted of 50mg of DCS or placebo, combined with two sessions of cocaine cue exposure and skills training. RESULTS:Participants demonstrated cocaine cue activation in a variety of brain regions at baseline. From the pre- to post-study scan, participants experienced decreased activation to cues in a number of regions (e.g., accumbens, caudate, frontal poles). Unexpectedly, placebo participants experienced decreases in activation to cues in the left angular and middle temporal gyri and the lateral occipital cortex, while DCSparticipants did not. CONCLUSIONS: Three trials of DCS-facilitated cue exposure therapy for cocaine dependence have found that DCS either increases or does not significantly impact response to cocaine cues. The present study adds to this literature by demonstrating that DCS may prevent extinction to cocaine cues in temporal and occipital brain regions. Although consistent with past research, results from the present study should be considered preliminary until replicated in larger samples.
Authors: L C Maas; S E Lukas; M J Kaufman; R D Weiss; S L Daniels; V W Rogers; T J Kukes; P F Renshaw Journal: Am J Psychiatry Date: 1998-01 Impact factor: 18.112
Authors: S Grant; E D London; D B Newlin; V L Villemagne; X Liu; C Contoreggi; R L Phillips; A S Kimes; A Margolin Journal: Proc Natl Acad Sci U S A Date: 1996-10-15 Impact factor: 11.205
Authors: Kerry J Ressler; Barbara O Rothbaum; Libby Tannenbaum; Page Anderson; Ken Graap; Elana Zimand; Larry Hodges; Michael Davis Journal: Arch Gen Psychiatry Date: 2004-11
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Matthew W Johnson; Natalie R Bruner; Patrick S Johnson; Kenneth Silverman; Meredith S Berry Journal: Exp Clin Psychopharmacol Date: 2019-08-01 Impact factor: 3.157
Authors: Anna B Konova; Muhammad A Parvaz; Vladimir Bernstein; Anna Zilverstand; Scott J Moeller; Mauricio R Delgado; Nelly Alia-Klein; Rita Z Goldstein Journal: Addict Biol Date: 2017-09-05 Impact factor: 4.280
Authors: Falk Kiefer; Martina Kirsch; Patrick Bach; Sabine Hoffmann; Iris Reinhard; Anne Jorde; Christoph von der Goltz; Rainer Spanagel; Karl Mann; Sabine Loeber; Sabine Vollstädt-Klein Journal: Psychopharmacology (Berl) Date: 2015-02-21 Impact factor: 4.530